1. Home
  2. CMS vs UTHR Comparison

CMS vs UTHR Comparison

Compare CMS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CMS Energy Corporation

CMS

CMS Energy Corporation

HOLD

Current Price

$75.70

Market Cap

21.8B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$542.90

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMS
UTHR
Founded
1987
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.8B
23.9B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
CMS
UTHR
Price
$75.70
$542.90
Analyst Decision
Buy
Buy
Analyst Count
14
14
Target Price
$78.38
$533.21
AVG Volume (30 Days)
2.3M
525.9K
Earning Date
04-23-2026
04-29-2026
Dividend Yield
3.03%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$2.06
$7.05
Revenue Next Year
$4.67
$13.30
P/E Ratio
$21.28
$19.13
Revenue Growth
N/A
2.38
52 Week Low
$67.71
$266.98
52 Week High
$78.88
$548.12

Technical Indicators

Market Signals
Indicator
CMS
UTHR
Relative Strength Index (RSI) 48.26 62.07
Support Level $75.66 $464.92
Resistance Level $76.69 N/A
Average True Range (ATR) 1.23 13.65
MACD -0.43 0.07
Stochastic Oscillator 33.69 92.61

Price Performance

Historical Comparison
CMS
UTHR

About CMS CMS Energy Corporation

CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: